American multinational Amgen have slashed the price of cholesterol drug Repatha, reducing the medication’s US list price by 60%.
The move, which is intended to boost sales, has seen Repatha’s list price drop from $14,000 to $5,850.
Murdo Gordon EVP Global Commercial Operations at Amgen suggested that the price cut, “is clearly focused on helping patients afford the medicine at the pharmacy counter.”
He added that the drug needed to be affordable for those on Medicare, the US government’s health plan for seniors.
Reageer